Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) presented a review of results to date from its multicenter BP-004 clinical trial of BPX-501 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE